학술논문
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis
Document Type
Academic Journal
Author
Source
The Journal of Allergy and Clinical Immunology. Sep 01, 2011 128(3):559-566
Subject
Language
English
ISSN
0091-6749
Abstract
BACKGROUND:: OBJECTIVES:: METHODS:: RESULTS:: The mean AAdSS was reduced by 36.0% and 34.5% at season 3 in the 2- and 4-month pre- and coseasonal active treatment groups, respectively, compared with that in the placebo group (P < .0001 for both). Reductions were observed in total symptom scores and ISSs and the medication score, with a marked improvement in quality of life for both active groups compared with the placebo group at season 3. Most treatment-emergent adverse events were local reactions expected with SLIT, decreasing in number and intensity in each treatment season. CONCLUSIONS